Abstract：
The value of treating asthma with the triple regimen of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA), and long-acting muscarinic antagonist (LAMA) delivered using multiple inhalers (MITT), or a single inhaler (SITT) is supported by a growing body of evidence, although research is still limited regarding the use of MITT.
Clinical characteristics, treatment patterns, disease burden, and persistence/adherence associated with MITT use in asthma. The MEDLINE database was searched to identify references from inception until October 2022.
The use of MITT is not very frequent in asthma patients, although it improves lung function and reduces the incidence of severe exacerbations. This may be due to existing concerns about using different devices on adherence and persistence to treatment, with a negative influence on outcomes, and to the fear that the patient will discontinue ICS/LABA but not LAMA. Nevertheless, although the current trend favors the SITT approach, some physicians may be induced to prescribe MITT over SITT because it allows the titration of individual components of triple therapy to be increased or decreased. Therefore, there is an evident need for pragmatic real-life studies to document when to prefer SITT and when MITT should be used.
Clinical characteristics, treatment patterns, disease burden, and persistence/adherence associated with MITT use in asthma. The MEDLINE database was searched to identify references from inception until October 2022.
The use of MITT is not very frequent in asthma patients, although it improves lung function and reduces the incidence of severe exacerbations. This may be due to existing concerns about using different devices on adherence and persistence to treatment, with a negative influence on outcomes, and to the fear that the patient will discontinue ICS/LABA but not LAMA. Nevertheless, although the current trend favors the SITT approach, some physicians may be induced to prescribe MITT over SITT because it allows the titration of individual components of triple therapy to be increased or decreased. Therefore, there is an evident need for pragmatic real-life studies to document when to prefer SITT and when MITT should be used.
摘要：
未经证实：吸入性皮质类固醇（ICS）三联方案治疗哮喘的价值，长效β2-激动剂（LABA），和使用多种吸入器（MITT）递送的长效毒蕈碱拮抗剂（LAMA），或者单个吸入器（SITT）得到越来越多证据的支持，尽管关于使用MITT的研究仍然有限。
未经证实：临床特征，治疗模式,疾病负担,以及与哮喘中MITT使用相关的持久性/依从性。为了识别参考,从数据库开始到2022年10月搜索MEDLINE数据库。
UASSIGNED：在哮喘患者中使用MITT不是很频繁，虽然它可以改善肺功能并降低严重加重的发生率。这可能是由于对使用不同设备对治疗依从性和持久性的影响的现有担忧。对结果有负面影响，并担心患者会停止ICS/LABA而不是LAMA。然而，尽管目前的趋势倾向于采用SITT方法，一些医生可能会被诱导开MITT而不是SITT,因为它允许增加或减少三联疗法的单个成分的滴定。显然,有必要进行务实的现实生活研究，以记录何时选择SITT以及何时使用MITT。
未经证实：临床特征，治疗模式,疾病负担,以及与哮喘中MITT使用相关的持久性/依从性。为了识别参考,从数据库开始到2022年10月搜索MEDLINE数据库。
UASSIGNED：在哮喘患者中使用MITT不是很频繁，虽然它可以改善肺功能并降低严重加重的发生率。这可能是由于对使用不同设备对治疗依从性和持久性的影响的现有担忧。对结果有负面影响，并担心患者会停止ICS/LABA而不是LAMA。然而，尽管目前的趋势倾向于采用SITT方法，一些医生可能会被诱导开MITT而不是SITT,因为它允许增加或减少三联疗法的单个成分的滴定。显然,有必要进行务实的现实生活研究，以记录何时选择SITT以及何时使用MITT。
